4 Midcap Quarterly Sales Growth and High Margin Stocks to Watch for Future Multibagger Potential: Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine

Quarterly sales growth and high margin stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine meet that test, with market caps from Rs 42,847 crore to Rs 86,889 crore and Max Healthcare offering the largest market cap at Rs 86,889 crore. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and latest quarter revenue growth of at least 15 per cent year on year and a latest quarter operating margin of at least 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and latest quarter revenue growth of at least 15 per cent year on year and a latest quarter operating margin of at least 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening quarterly sales growth and high margin stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 29 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Quarterly Sales Growth and High Margin Stocks and Why Do They Attract Multibagger Interest?

Quarterly sales growth and high margin stocks are shares of mid sized companies that grew sales by fifteen per cent or more in the latest quarter and kept an operating margin of twenty per cent or more, a sign of strong demand and strong pricing at the same time. The four here cover hospitals, specialty chemicals and fluorine products.

Fast sales growth with a high margin in the same quarter shows that the company is not buying growth with discounts, and that it keeps a good share of every rupee it sells. Within quarterly sales growth and high margin stocks, the four companies show rising profit. For quarterly sales growth and high margin stocks, both FY26 and the latest quarter showed growth. Whichever way you read quarterly sales growth and high margin stocks, the common thread is rising profit backed by complete financial data. With quarterly sales growth and high margin stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for quarterly sales growth and high margin stocks are complete. Read each company's latest results and exchange filings before acting on quarterly sales growth and high margin stocks.

Quarterly Sales Growth and High Margin Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 29 October 2026. SRF has the lowest PE of the group at 34.61, while Navin Fluorine posts the highest return on equity at 16.69%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Max Healthcare Institute	851.15	86,889	59.63	60.75	13.42%	0.32	815.00 to 1,221.90
SRF	2,358.60	74,824	34.61	36.15	13.07%	0.36	2,310.00 to 3,210.00
Fortis Healthcare	754.90	57,464	53.68	60.75	10.53%	0.35	565.00 to 759.50
Navin Fluorine International	8,260.50	42,847	54.26	36.42	16.69%	0.32	4,772.20 to 8,949.50

Max Healthcare: 24.26% Profit CAGR Since FY22

Max Healthcare Institute runs a network of multi-speciality hospitals in Delhi NCR, Mumbai and other cities. It reported FY26 revenue of Rs 8,536.07 crore, up 18.82% year on year, and net profit of Rs 1,442.41 crore, up 34.07%. Net profit has compounded at 24.26% a year since FY22, while revenue has grown 20.42% a year. Operating margin was 28.15% in FY26. The debt-to-equity ratio is 0.32.

In the June 2026 quarter, revenue rose 16.60% to Rs 2,406.69 crore and net profit grew 4.87% to Rs 322.96 crore. The share price has gained 149.91% over five years. Domestic institutions raised their holding from 17.42% in June 2025 to 29.96% in June 2026. The stock trades at a PE of 59.63 against an industry PE of 60.75, below the sector average, with a return on equity of 13.42%.

SRF: Quarterly Profit Up 75.53%

SRF operates in specialty chemicals, packaging films and technical textiles, and its chemicals business is a key earnings driver. It reported FY26 revenue of Rs 15,893.57 crore, up 7.20% year on year, and net profit of Rs 1,835.18 crore, up 46.72%. Revenue has compounded at 6.08% a year since FY22. Operating margin was 21.74% in FY26. The debt-to-equity ratio is 0.36.

The stock trades at a PE of 34.61 against an industry PE of 36.15, below the sector average, with a return on equity of 13.07%. In the June 2026 quarter, revenue rose 31.69% to Rs 5,067.17 crore and net profit grew 75.53% to Rs 758.87 crore. Domestic institutions raised their holding from 18.85% in June 2025 to 22.44% in June 2026.

Fortis Healthcare: Five-Year Gain of 241.47%

Fortis Healthcare operates a chain of hospitals and diagnostic centres across India. It reported FY26 revenue of Rs 9,178.50 crore, up 16.93% year on year, and net profit of Rs 1,064.19 crore, up 31.48%. Net profit has compounded at 7.73% a year since FY22, while revenue has grown 12.43% a year. Operating margin was 22.41% in FY26. The debt-to-equity ratio is 0.35.

In the June 2026 quarter, revenue rose 17.29% to Rs 2,559.50 crore and net profit grew 2.26% to Rs 272.80 crore. The share price has gained 241.47% over five years. Domestic institutions raised their holding from 29.79% in June 2025 to 32.23% in June 2026. The stock trades at a PE of 53.68 against an industry PE of 60.75, below the sector average.

Navin Fluorine: 26.02% Profit CAGR Since FY22

Navin Fluorine International makes specialty fluorochemicals, refrigerant gases and contract research and manufacturing services. It reported FY26 revenue of Rs 3,379.19 crore, up 41.20% year on year, and net profit of Rs 663.56 crore, up 129.92%. Net profit has compounded at 26.02% a year since FY22, while revenue has grown 22.66% a year. Operating margin was 34.41% in FY26. The debt-to-equity ratio is 0.32.

The stock trades at a PE of 54.26 against an industry PE of 36.42, with a return on equity of 16.69%. In the June 2026 quarter, revenue rose 46.11% to Rs 1,080.17 crore and net profit grew 107.66% to Rs 243.31 crore. The share price has gained 111.47% over five years and 61.62% over the past year. Foreign investors raised their holding from 21.98% in July 2025 to 23.73% in June 2026.

Quarterly Sales Growth and High Margin Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these quarterly sales growth and high margin stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
Max Healthcare	8,536.07	1,442.41	18.82%	20.42%	16.60%	27.00%
SRF	15,893.57	1,835.18	7.20%	6.08%	31.69%	25.73%
Fortis Healthcare	9,178.50	1,064.19	16.93%	12.43%	17.29%	22.22%
Navin Fluorine	3,379.19	663.56	41.20%	22.66%	46.11%	37.52%

Check the Univest Screener for live data on these quarterly sales growth and high margin stocks

Institutional Holding in Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine

Institutional holding shows who is backing these quarterly sales growth and high margin stocks alongside the promoter. The table uses the latest reported quarter for each. Max Healthcare has the deepest institutional backing, with FII and DII together holding 71.74% as of June 2026. Domestic institutions increased their holding over the past year in Max Healthcare (from 17.42% to 29.96%), SRF (from 18.85% to 22.44%) and Fortis Healthcare (from 29.79% to 32.23%).

Stock	Promoter	FII	DII	Public	Quarter
Max Healthcare	23.71%	41.78%	29.96%	4.56%	June 2026
SRF	50.26%	15.45%	22.44%	11.85%	June 2026
Fortis Healthcare	31.17%	25.20%	32.23%	11.40%	June 2026
Navin Fluorine	27.08%	23.73%	28.46%	20.73%	June 2026

Risks to Weigh in Quarterly Sales Growth and High Margin Stocks

Being careful with quarterly sales growth and high margin stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Navin Fluorine trades at a PE of 54.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Quarterly Sales Growth and High Margin Stocks

Picking from quarterly sales growth and high margin stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.15 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine live prices.

Conclusion

Among quarterly sales growth and high margin stocks, Max Healthcare stands out for the largest market cap at Rs 86,889 crore, SRF for the lowest PE of the group at 34.61, Fortis Healthcare for the biggest five-year price gain at 241.47% and Navin Fluorine for the highest return on equity at 16.69%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing quarterly sales growth and high margin stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Quarterly Sales Growth and High Margin Stocks to Watch

Which are the best quarterly sales growth and high margin stocks to watch for multibagger potential?

Ans. Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine are the 4 names this list highlights, with market caps of Rs 86,889 crore, Rs 74,824 crore, Rs 57,464 crore and Rs 42,847 crore respectively. Max Healthcare is notable for the largest market cap at Rs 86,889 crore. SRF stands out for the lowest PE of the group at 34.61. Fortis Healthcare offers the biggest five-year price gain at 241.47%. Navin Fluorine brings the highest return on equity at 16.69%. These are watchlist names for quarterly sales growth and high margin stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Navin Fluorine a good stock for long-term investors?

Ans. Navin Fluorine has a return on equity of 16.69%, a PE of 54.26 against an industry PE of 36.42 and a market cap of Rs 42,847 crore. Net profit has compounded at 26.02% a year since FY22, and FY26 revenue rose 41.20% while June 2026 quarter net profit grew 107.66%. Long-term returns in quarterly sales growth and high margin stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Max Healthcare become a multibagger from here?

Ans. Max Healthcare has already gained 149.91% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in quarterly sales growth and high margin stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.26% a year since FY22, and FY26 revenue rose 18.82%. At a PE of 59.63 against an industry PE of 60.75, valuation should be checked against that growth before investing.

What is the market cap of Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine?

Ans. As of 29 October 2026, Max Healthcare has a market cap of Rs 86,889 crore, SRF has a market cap of Rs 74,824 crore, Fortis Healthcare has a market cap of Rs 57,464 crore and Navin Fluorine has a market cap of Rs 42,847 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on quarterly sales growth and high margin stocks.

What are the risks of investing in quarterly sales growth and high margin stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Navin Fluorine trades at a PE of 54.26 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Navin Fluorine trading at a PE of 54.26?

Ans. Navin Fluorine's PE of 54.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 16.69%, profit growth of 26.02% a year since FY22 and latest-quarter profit growth of 107.66%, which also means the stock is more sensitive if growth slows. Investors in quarterly sales growth and high margin stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Max Healthcare, SRF, Fortis Healthcare and Navin Fluorine?

Ans. As of the latest reported quarter, FII and DII together hold 71.74% of Max Healthcare (41.78% and 29.96%), 37.89% of SRF (15.45% and 22.44%), 57.43% of Fortis Healthcare (25.20% and 32.23%) and 52.19% of Navin Fluorine (23.73% and 28.46%). Rising institutional holding is a useful signal in quarterly sales growth and high margin stocks, though it should be read with earnings trends rather than on its own.